Mesalazine in Inflammatory Bowel Disease: A Trendy Topic Once Again?

Iacucci, Marietta; Silva, Shanika de; Ghosh, Subrata

doi:10.1155/2010/586092

Cited by 109 publications

(69 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was rapidly determined that compounds such as salicylazosulphapyridine in particular were metabolized by gut microbes (Cooke, 1969), due to differential product metabolite profiles in germ-free and antibiotic-treated animals (Peppercorn and Goldman, 1972). Again, though, changes in microbial load or profile were modest (West et al, 1974), and the mechanism of action of 5-ASAs and their effects on the gut microbiome remain complex (Iacucci et al, 2010; Morgan et al, 2012). Treatments for IBD provided another route by which the role of the gut microbiome could be explored, however, since microbial changes induced by compounds alleviating disease might help elucidate the still-missing host-microbe links.…”

Section: The Complex Interplay Of Host and Microbe In Ibdmentioning

confidence: 99%

Inflammatory Bowel Disease as a Model for Translating the Microbiome

2014

View full text Add to dashboard Cite

The inflammatory bowel diseases (IBD) are among the most closely studied chronic inflammatory disorders that involve environmental, host genetic, and commensal microbial factors. This combination of features has made IBD both an appropriate and a high-priority platform for translatable research in host-microbiome interactions. Decades of epidemiology have identified environmental risk factors, although most mechanisms of action remain unexplained. The genetic architecture of IBD has been carefully dissected in multiple large populations, identifying several responsible host epithelial and immune pathways but without yet a complete systems-level explanation. Most recently, the commensal gut microbiota have been found to be both ecologically and functionally perturbed during the disease, but with as-yet-unexplained heterogeneity among IBD subtypes and individual patients. IBD thus represents perhaps the most comprehensive current model for understanding the human microbiome’s role in complex inflammatory disease. Here, we review the influences of the microbiota on IBD and its potential for translational medicine.

show abstract

Section: The Complex Interplay Of Host and Microbe In Ibdmentioning

confidence: 99%

Inflammatory Bowel Disease as a Model for Translating the Microbiome

2014

View full text Add to dashboard Cite

show abstract

“…Mesalazine has not been shown to be superior to placebo for maintaining medically induced remission, however, it may have a modest effect in surgically induced remission for patients without risk factors for recurrent surgery (such as mucosal ulceration, smoking, or predictors of disabling course) (32). Recently, the American and the British National Gastroenterology Associations have recommended the use of high-dose 5-ASA for the first-line treatment of mild ileal, ileocolonic or colonic CD (31). In our case, patient's bowel symptoms were improved by surgical resection of the obstruction and mesalazine was used as a preventive therapy after surgery.…”

Section: Discussionmentioning

confidence: 74%

“…5-aminosalicylic acid (5-ASA) preparations are well-established preparations used in the management of inflammatory bowel disease (31,32). Medical therapy outcomes and clinical trials of these medications are often categorized by their ability to achieve induction of response or remission during a period of active disease, to maintain medically induced remission, or to maintain surgically induced remission (32).…”

Section: Discussionmentioning

confidence: 99%

“…Medical therapy outcomes and clinical trials of these medications are often categorized by their ability to achieve induction of response or remission during a period of active disease, to maintain medically induced remission, or to maintain surgically induced remission (32). These drugs are most useful for the treatment of mild to moderate flares of ulcerative colitis and, especially, for maintenance of remission (31). However, there is conflicting evidence regarding the efficacy of oral 5-ASA in active CD and their use in mild to moderate CD has been debated.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Limited form of wegener’s granulomatosis in a patient with Crohn’s disease. A case report

Salah

Frikha²,

Snoussi³

et al. 2015

Turk J Gastroenterol

View full text Add to dashboard Cite

Wegener's granulomatosis (WG) is a multisystemic disease of unknown etiology characterized by necrotizing vasculitis and granulomatous inflammation. Although, the gastrointestinal tract can be involved in this vasculitis, the association between WG and Crohn's disease (CD) exists and was previously described. We report the case of a 29 year-old Tunisian white patient previously diagnosed with CD, presenting 3 years later with a perforated nasal septum, mucosal ulcers and sinusitis. He had also a skin ulcerative eruption of the trunk. There was no evidence of a flare of his CD. A computed tomography scan of the head showed nasal septal perforation, and maxillary pansinusitis. A biopsy from the nasal septum demonstrated nasal mucosa with extensive necrotizing granulomatous reaction associated with vasculitis. The patient was diagnosed as having limited form of Wegener's granulomatosis. He was treated with prednisone 60 mg/day and methotrexate 15 mg weekly. After Two months of treatment, he had no complaints, skin eruption and orofacial lesions were improved. Although, the gastrointestinal tract can be involved in patients with WG, the association with a CD exists and was previously described. The distinction between the two conditions and their possible coexistence is very important and requires histological examination of involved tissue. Keywords: Crohn's disease, vasculitis; Wegener's granulomatosis, corticoid therapy INTRODUCTION Wegener's granulomatosis (WG) is a necrotizing vasculitis of the small to medium-sized arteries characterized by involvement of the upper and lower respiratory tract and the kidneys (1-3). Although, the gastrointestinal tract can be involved in 10%-24% of patients with WG (4-8), the association with a Crohn's disease (CD) exists and was previously described (9,10). The distinction between the two conditions and their possible coexistence requires histological examination of involved tissues. We describe a patient previously diagnosed with CD, presenting 3 years later with a perforated nasal septum and histological evidence of nasal granulomas and ultimately diagnosed as having WG. CASE PRESENTATIONA 29-year-old year-old Tunisian white man first developed a chronic profuse diarrhea with blood and mucus in 2008. He consulted in gastroenterology. The colonoscopy revealed multiple, deep, irregular ulcers of rectosigmoid mucosa. The rest of the colon was normal to the cecum. The ileal mucosa was ulcerated and very inflammatory. The histological diagnosis was consistent with CD, based on transmural inflammatory process including fissure ulcers and the finding of many lymphoid follicles in the subserosa with several non-necrotizing granuloma. He was subsequently treated for one year with mesalazine (2 g per day per os) with rapid resolution of the diarrhea. Intermittent bloody diarrhea had exacerbated Case Report Turk J Gastroenterol 2014; 25 (Suppl.-1): 191-5 Thereafter, intermittent bloody diarrhea was improved and mesalazine alone was used to maintain surgically induced remiss...

show abstract

“…The clinical goals of IBD treatment are to control inflammation, achieve mucosal healing, and reduce surgeries and hospitalizations [2,3]. Traditional treatment strategies have been limited to the daily administration of high doses of medications, including biologic therapies, corticosteroids, immunomodulators, aminosalicylates, and antibiotics [4,5].…”

Section: Introductionmentioning

confidence: 99%